5 patents currently held
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2038. from the record
Of the 8 now held by other companies, 1 name Dust Biosolutions GmbH as their current owner, and 7 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2038
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2040 · High confidence
Also notable
Ends Feb 2038 · High confidence
Also notable
Ends Mar 2040 · High confidence
Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA
US 11,441,148
The earliest of the three still in force, granted 2022 and renewed since. Its term ends first, in 2040.
Novel Treatment for NEAT1 Associated Disease
US 11,459,563
The earliest of the three still in force, granted 2022 and renewed since. Its term ends first, in 2038.
Methods for Treating VEGF-Related Conditions
US 11,786,611
The newest of the three, granted 2023. It anchors the portfolio to 2040, later than anything else here.
Formerly held, still cited
Notable
Ends Sep 2034 · High confidence
Cited by 15 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2034.
now held by Sarepta Therapeutics, Inc.
Also notable
Ends May 2028 · High confidence
The most cited patent in this portfolio, cited by 30 later US patents, top 25% of utility patents granted in 2012 in our data. Protection runs to 2028.
now held by Dust Biosolutions GmbH
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA (US 11,674,143) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due Apr 17, 2027The maintenance fee for Methods for Treating VEGF-Related Conditions (US 11,786,611) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
Recent changes
- Nov 5Assignment recorded on 1 record: Veedu, Rakesh N. to Murdoch University Recorded Nov 5, 2026, executed Nov 5, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76639, frame 602.
- Sep 28Assignment recorded on 1 record: Wilton, Stephen and 1 other to Murdoch University Recorded Sep 28, 2026, executed Apr 14, 2014. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76572, frame 575.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | 3 in force | to May 2040 |
| Methods for Treating VEGF-Related Conditions | 1 in force | to Mar 2040 |
| Novel Treatment for NEAT1 Associated Disease | 1 in force | to Feb 2038 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,459,563 | Novel Treatment for NEAT1 Associated Disease In force · High confidence | In force | High confidence | |
| US 11,786,611 | Methods for Treating VEGF-Related Conditions In force · High confidence | In force | High confidence | |
| US 11,441,148 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA In force · High confidence | In force | High confidence | |
| US 11,674,143 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA In force · High confidence | In force | High confidence | |
| US 12,565,656 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 8 patents in force now held by others · 3 patents ended · 13 applications pending · 19 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.